PYXS
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Pyxis Oncology reported positive updated Phase 1 monotherapy data for MICVO in second-line and later recurrent or metastatic HNSCCSep 9, 2026
- Pyxis Oncology's Phase 1 MICVO study achieved a 36% confirmed ORR and 94% DCR in recurrent or metastatic HNSCC, with Phase 3 planned for 2027Sep 9, 2026
- Pyxis Oncology reports positive preliminary Phase 1 data for MICVO in head and neck cancerDec 18, 2025